Life sciences-focused private equity firm BVCF has completed a third fund that will target China-based investments, and Novartis is amongst the backers.
China-based private equity firm BVCF has closed its third fund at $200m, with investors in the fund including Switzerland-based healthcare company Novartis, according to Asian Venture Capital Journal.
Founded in 2005 under the name BioVeda China, BVCF is a dedicated life sciences investor, and its investments have included Citic Pharmaceuticals, which was sold to the state-owned Shanghai Pharmaceuticals in 2010, MicuRx Pharmaceuticals, Novast and Souzhou Ribo Life Science. Its first fund closed in 2005 at $21m and its second in…
